Tuberculosis is a leading cause of morbidity and mortality for persons with human immunodeficiency virus (HIV) infection worldwide [1] . Incidence of tuberculosis remains higher than that observed in non-HIV-infected persons even in patients treated with combined antiretroviral therapy (cART) [2] [3] [4] [5] [6] . According to the data of a collaborative European cohort study, a diagnosis of tuberculosis represents 22% of all AIDS-defining events in European countries [7] . In addition, almost one-third of patients with newly diagnosed HIV infection present with an AIDS-defining event or with a low CD4 T-cell count [8] , and they may not completely benefit from the effect of cART.
Mechanisms underlying poor immunological outcome during cART and predictors are still to be completely defined [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . In particular, little is known about the rate and magnitude of CD4 T-cell count recovery in persons who start cART during an opportunistic infection, and whether this response varies with specific infections.
It is possible that tuberculosis may affect the long-term chance of immune restoration via 2 separate mechanisms: first by increasing apoptosis of CD4 T cells and decreasing probability of immune restoration [19] , and second by affecting viral suppression due to difficulties in patients' management [20] . To analyze the potential impact of tuberculosis on the rate of CD4 T-cell count increase after the initiation of cART, we established a collaborative analysis that included patients presenting with tuberculosis when they were enrolled in 4 Italian clinical cohorts.
METHODS

Patients and Methods
Clinical data were pooled from 4 cohorts enrolling HIV-infected patients in Italy: the Icona Foundation Study, a cohort of HIVinfected patients enrolled when they are antiretroviral naive at 50 different sites; the National Institute for Infectious Dieases (INMI) Spallanzani Clinical cohort in Rome; the Infectious Diseases Database San Raffaele in Milan, Italy; and the Catholic University Sacred Heart (UCSC) clinical cohort, Rome. The latter 3 are clinical databases of HIV-infected patients enrolled at the time of their first contact with the clinic. In each cohort, patients were followed up with common monitoring procedures and at similar time points, although CD4 T-cell count were measured more frequently in Infectious Diseases Database San Raffaele and Icona (every 6 months on average) than in INMI and UCSC (yearly collection). We defined cART as a regimen with $3 antiretroviral drugs from all the major drug classes. Diagnosis of AIDS-defining clinical events was performed according to international standards [21] ; the diagnosis of tuberculosis was based on microbiological criteria (detection of acid-fast bacilli, growth on culture, and/or Mycobacterium tuberculosis nucleic acid detection in biological fluids) or clinical or radiological criteria and response to antituberculosis treatment.
All patients starting cART over the period 1996-2010 without previous exposure to any suboptimal antiretroviral therapy (ART) were eligible for this analysis if they had $1 CD4 T-cell count measurement before starting cART and another measurement during follow-up.
Statistical Analysis
Participants were classified into 3 groups according to whether they had tuberculosis, had nontuberculosis AIDS, or were AIDS free (comparator group) around the time of cART initiation (a time window ranging from 6 months before to 6 months after starting cART). We did not choose patients with nontuberculosis AIDS for the comparator group because other pathogens causing AIDS-related conditions may potentially play a confounding role in immune recovery.
Three primary end points were defined as the time to achieve (1) a CD4 T-cell count of 100 cells/lL, (2) 200 cells/lL, or (3) 300 cells/lL above pre-cART levels. The time to achieve an absolute CD4 T-cell count threshold of 500 cells/lL was considered as a secondary end point. Two different time points were considered as time 0 for these survival analyses: the time of starting cART or the first time at which HIV RNA level was #50 copies/mL. This second time point was chosen to remove factors associated with poor virological response, such as adherence to medications. In this second analysis, if a participant's CD4 T-cell count had increased above the event-defining threshold before baseline, then he or she was excluded. In addition, we also evaluated the time from starting cART to achieving a viral load of #50 copies/mL. The hypothesis of a possible interaction between antituberculosis treatment and antiretrovirals was tested by (1) classifying patients according to whether antituberculosis treatment was initiated before ART and was still ongoing at the time of ART initiation or whether antituberculosis treatment was completed before ART initiation or started after ART and (2) fitting an interaction term in the model. This was done overall and after restricting the analysis only to participants who started a boosted protease inhibitor (PI) regimen. Because the end of antituberculosis treatment was not recorded in the databases, we assumed 6 months of antituberculosis treatment after the start date for everybody with a diagnosis of tuberculosis.
Standard survival analysis with time-fixed and time-dependent covariates was used, censoring patients' follow-up at the time of their last CD4 T-cell count measurement. In the analysis with time 0 as the time of first reaching a viral load of #50 copies/mL, patients' follow-up was also censored at the time of viral rebound to .500 copies/mL (first of 2 consecutive values). The focus was on CD4 T-cell count recovery with a first-line regimen, and therefore patients were no longer contributing person-years to the analysis after experiencing viral failure of their first regimen. In the analysis of the time to virological suppression, the date of last viral load measurement was used for censoring. Kaplan-Meier curves, stratified by the groups defined above, were used to compare their cumulative probability of reaching the defined end points. A proportional hazard Cox regression model was used to estimate the relative hazard [RH] of reaching the same end points after controlling for a number of possible confounding factors (see Table 3 for details). The proportionality hazards assumption was checked using graphical tests such as plotting the log (2log [survival]) versus log of survival time (parallel lines; not shown) and the test for a nonzero slope of the scaled Schoenfeld residuals as function of time developed by Therneau and Grambsch [22] .
RESULTS
Baseline Patient Characteristics
A total of 6528 patients were eligible for this analysis and were followed up for a median of 21 months (interquartile range [IQR], 10-38 months). Baseline characteristics of the included patients are described in Table 1 . Eighty-one percent of patients were Italian-born. The median baseline count of CD4 T cells was 269 cells/lL and 64% of patients had ,350 cells/lL; 63% of patients started PI-based cART regimens.
A diagnosis of tuberculosis was given to 125 patients (2%). On average, the diagnosis was made a median of 1 week before ART initiation (IQR, 60 days before to 4 days after ART initiation). One hundred sixteen patients had pulmonary tuberculosis (72.9%), whereas 43 patients had extrapulmonary tuberculosis (27.1%). A nontuberculosis AIDS-defining event was observed in 1061 patients (for details see Table 1 ). These diagnoses were performed a median of 4 days before starting ART (IQR, 36 days before to 0 days after starting ART), whereas 5341 (82%) patients started cART in the absence of any AIDS-defining clinical event. Groups seem to differ with respect to baseline characteristics; in particular, patients with tuberculosis were younger (P , .001), had lower CD4 T-cell counts at baseline (P , .001), and were less likely to be Italian-born (P , .001, Table 1 ) than AIDS-free patients.
Immunological Outcomes
The probabilities of achieving a gain of .100, .200, or .300 CD4 T cells/lL from baseline is shown in Figure 1A -D. The Kaplan-Meier estimates of the median time to achieve an increase of .100, .200, and .300 CD4 T cells/lL above pre-cART values from the start of cART were 7.9 months (95% confidence interval [CI], 7-8 months), 18 months (95% CI, 17-19 months), and 34 months (95% CI, 32-36 months), respectively. Fifty percent of the patients have achieved a CD4 T-cell count of .500 cells/lL by 24 months (95% CI, 22-25 months) from the start of cART.
For all 3 primary outcomes, the patients with tuberculosis showed a significantly reduced probability of CD4 T-cell count recovery when compared with both other patients with AIDS and AIDS-free patients, other patients with AIDS alone, or AIDS-free patients alone ( Figure 1A-C) , whereas for the outcome of reaching the absolute value of .500 CD4 T cells/lL, AIDS-free patients did significantly better than patients with AIDS, but there was no difference between patients with tuberculosis and patients presenting with other AIDS-defining conditions ( Figure 1D ). Note that only 5364 patients whose CD4 T-cell count was not already .500 cells/lL before starting cART were included in this analysis (Table 1) .
After controlling for pre-cART viral load (as well other time-fixed factors listed in Table 2 ), patients with tuberculosis had a significantly reduced chance of CD4 T-cell count increase compared with that of AIDS-free patients regardless of the primary outcome considered (Table 2) , whereas only a residual association between tuberculosis and CD4 T-cell count gain response was observed after further adjustment for current level of viral load suppression below pre-cART levels ( Table 2 ). In this analysis that controlled for confounding factors at baseline, we also detected a clear tendency for a difference between patients with tuberculosis and those with other AIDS-defining diagnoses, especially for a CD4 In addition, for patients with nontuberculosis AIDS, a difference from AIDS-free patients was observed only for the outcome of a gain of 100 CD4 T cells/lL above pre-cART levels ( Table 2) . After controlling for potential confounders including current change in viral load, compared with AIDS-free patients, the RHs for achieving an absolute count of .500 cells/lL were 0.92 (95% CI, .64-1.32; P 5 .65) for participants with tuberculosis and 1.00 (95% CI, .87-1.15; P 5 .99) for those with other AIDS-defining illnesses. Results were similar after restricting the analysis to patients with an AIDS diagnosis (including tuberculosis) occurring before cART initiation, as well as after controlling for duration of time since first HIV-positive test instead of year of HIV diagnosis (data not shown). Table 3 shows the results of the Cox regression analysis evaluating the probability of an increase in CD4 T-cell counts above levels observed at time of viral load suppression. Unlike what observed in the main analysis, we found no difference between the groups.
Virological Outcomes
Overall, 5476 participants (74%) achieved a viral load of #50 copies/mL at some point after starting cART. The median time to viral suppression was 20 months (95% CI, 15-31 months), 15 months (95% CI, 14-18 months), and 14 months (95% CI, 13-15 months) for patients with tuberculosis, patients with nontuberculosis AIDS, and AIDS-free patients, respectively (P 5 .09; log-rank test). Of these, 5311 patients (97%) had a viral load of #50 copies/mL that persisted for $2 consecutive measurements and $1 CD4 T-cell count after the date of suppression and were included in the analysis of the CD4 T-cell count recovery after virological suppression outcomes. We detected no difference between the AIDS and tuberculosis groups regarding the periods of time to achieve a viral load of #50 copies/mL after controlling for a number of potential confounders (Table 4 ). In this analysis we found that both baseline CD4 T-cell count (RH, 0.96 per 100-cells/lL increase; 95% CI, 2.94 to .97; P 5 .0001) and type of ART were strongly associated with the outcome (patients who started a single PI regimen were less likely to achieve suppression than those starting a nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based regimen; RH, 0.71; 95% CI, 2.65 to .78; P 5 .0001). Finally, we investigated the effect of a potential interaction between antituberculosis treatment and ART on the chance of achieving a viral load of #50 copies/mL. Participants were grouped according to whether patients were still receiving antituberculosis treatment at the time of starting ART (n 5 44) or not receiving antituberculosis treatment at ART initiation (n 5 112), and the analysis was stratified accordingly (3 cases of tuberculosis were excluded because no virological follow-up was available). The adjusted RHs of achieving viral suppression of patients with tuberculosis compared with AIDSfree patients were 1.17 (95% CI, .86-1.60) in patents who started ART while antituberculosis treatment was ongoing and 0.75 (95% CI, .42-1.33) in those for whom antituberculosis treatment was completed or was started after cART initiation (P 5 .09). The difference was even more marked when the analysis was restricted to patients who started a boosted PI regimen (data not shown). Results were similar in a number of sensitivity analyses by grouping patients according to whether the date of treatment of tuberculosis was recorded before or after the date of initiation of cART (data not shown).
DISCUSSION
In this study, HIV-infected patients starting cART when ART naive and with a tuberculosis diagnosis had an impaired immune recovery compared with those who were AIDS free. We also detected a significant difference between patients with tuberculosis and those with other AIDS-defining diagnoses for 2 of 3 immunological end points considered. This impairment seems to be persistent over 3 years of observation and is mainly explained by differences in the level of viral suppression between patients with and those without tuberculosis. Indeed, although the association remained significant after adjustment for baseline factors, most of the effect was explained by current change in viral load levels. In turn, virological response to therapy varied according to baseline CD4 T-cell count and type of ART started. When the analysis was restricted to patients who did achieve viral suppression, again the chance of CD4 T-cell count recovery was not affected by a diagnosis of tuberculosis (or AIDS) at the time of starting cART. Abbreviations: cART, combined antiretroviral therapy; CDC, Centers for Disease Control and Prevention; CI, confidence interval; RH, relative hazard. a Adjusted for age, pre-cART CD4 T-cell count, pre-cART CD8 T-cell count, pre-cART viral load, hepatitis C or B virus coinfection, year of human immunodeficiency virus (HIV) test, year of cART initiation, sex, mode of HIV transmission, Italian nationality, and type of cART started. b Adjusted for age, pre-cART CD4 T-cell count, pre-cART CD8 T-cell count, current change in viral load, hepatitis C or B virus coinfection, year of HIV test, year of starting cART, sex, mode of HIV transmission, Italian nationality, and type of cART started. c Global multivariable P value. Ex vivo and in vitro studies have shown that during chronic HIV infection, M. tuberculosis-specific CD4 T-cell responses are significantly decreased in the periphery and bronchoalveolar lavage [23] [24] [25] , which is different from responses to other pathogens, such as cytomegalovirus [26] . Moreover, these cells are more susceptible to HIV infection [23, 26, 27] and can be induced to produce HIV [28] . These data support the hypothesis that direct HIV infection of M. tuberculosisspecific CD4 T cells contributes to their depletion, possibly compromising the generation of effective immune responses to M. tuberculosis and immunological recovery after starting cART.
Analyses evaluating the effect of AIDS-defining events (including tuberculosis) on the immunological response to cART showed conflicting results. Patients affected by Toxoplasma gondii encephalitis (another intracellular pathogen like M. tuberculosis) at the time of starting cART were at higher risk of an impaired CD4 T-cell count increase than patients with Pneumocystis jirovecii pneumonia [29] ; in addition, Mycobacterium avium complex infection has been shown to be a risk factor for immune reconstitution [30] . Conversely, a recent multicenter Spanish study reported no association of the magnitude of immune recovery after starting cART with the presence of AIDS-defining illnesses [31] .
A correlation between viral replication and expression of immune activation markers and the role of cART in reducing the immune activation are both widely reported [32, 33] . Because HIV and tuberculosis coinfection has been associated with higher level of immune activation markers [27, 34, 35] , it could be hypothesized that residual immunoactivation is even more of an issue in patients with HIV and tuberculosis coinfection than in HIV-infected patients, despite virologically suppressive cART. In our analysis, however, there was no residual effect of tuberculosis on CD4 T-cell count recovery after we restricted the analysis to those who responded virologically to cART, even though we cannot draw any definitive conclusion without specific study of the immunoactivation markers.
There are only a few clinical studies on immune recovery during cART in patients with tuberculosis. Data from South Africa showed no effect of tuberculosis on immune recovery although only a small proportion of patients (,25%) in the study were followed up for 48 weeks [36] . In a more recent analysis, the occurrence of tuberculosis during the first 12 months of therapy was independently associated with poor long-term CD4 T-cell count recovery [18] . In contrast, the results of a randomized clinical trial of concomitant antituberculosis and antiretroviral treatment versus antituberculosis treatment alone indicates that the addition of cART during antituberculosis treatment in patients with preserved CD4 T-cell count does not result in additional improvement of T-cell activation [37] .
HIV and tuberculosis coinfection is characterized by several challenges in term of patients' management, such as poor adherence and overlapping toxicities. In addition, interactions with antituberculosis treatment may cause reduced plasma concentration of antiretrovirals, resulting in a reduced chance of virological success. A recent analysis in a cohort of HIV-and tuberculosiscoinfected patients showed that concurrent treatment for tuberculosis was associated with a lower rate of viral suppression in patients receiving PI-based regimens but not in those receiving NNRTI-based regimens [38] . Indeed, our analysis consistently shows that patients who started cART when their antituberculosis treatment was ongoing tended to have a lower chance of achieving optimal virological response to cART compared with AIDS-free patients, whereas there was a trend in the opposite direction for patients who either had completed their antituberculosis treatment when they started cART or were treated for tuberculosis after cART initiation. Interestingly, the interaction was even more significant after the analysis was restricted to patients who started a boosted PI regimen. We therefore hypothesize that our patients with tuberculosis had an impaired CD4 T-cell recovery with cART because of the effect of drug-drug interaction on viral response, which, in turn, affected CD4 T-cell count.
Because of the time window for inclusion, we cannot exclude the possibility that some of the tuberculosis cases observed in our study were indeed cART-associated tuberculosis [39] . Nevertheless, this hypothesis does not seem to be supported by results from recent analyses showing impaired immunological outcomes both in patients who developed clinically recognizable tuberculosis after starting cART (unmasked tuberculosis) and in those who, after starting cART, experienced a worsening of preexisting tuberculosis signs and symptoms [40] . Our study has several limitations. First, because this was a retrospective cohort study, we cannot evaluate the role of immune reconstitution syndrome in the pathogenesis of tuberculosis cases. Second, there was no plan to use stored plasma samples of participants for this collaborative analysis, and therefore we do not have pharmacokinetic data that could substantiate the clinical hypothesis of detrimental interaction between antituberculosis treatment and cART. Moreover, because of the observational nature or our studies, we cannot exclude the presence of unmeasured confounding, such as differential rate of response to antituberculosis treatment or adherence.
In conclusion, our analysis showed that HIV-infected patients starting cART when ART naive and with a tuberculosis diagnosis have an impaired immune recovery with cART, mainly because of differences in level of viral suppression between them and both patients with nontuberculosis AIDS and those without AIDS. Further studies need to be performed to determine whether our findings may be explained by pharmacokinetic interactions between the 2 treatments or to specific interactions between M. tuberculosis and HIV or both. Nevertheless, our results suggest that strategies aimed at preventing tuberculosis cases may increase the chances of virological and immunological response to cART.
Notes
